人细小病毒B19通过凝血因子浓缩物传播。

Transmission of human parvovirus B19 by coagulation factor concentrates.

作者信息

Williams M D, Cohen B J, Beddall A C, Pasi K J, Mortimer P P, Hill F G

机构信息

Haematology Department, Children's Hospital, Birmingham, UK.

出版信息

Vox Sang. 1990;58(3):177-81. doi: 10.1111/j.1423-0410.1990.tb02086.x.

DOI:10.1111/j.1423-0410.1990.tb02086.x

PMID:2160147

Abstract

The prevalence of antibody to human parvovirus B19 was determined in 86 children with congenital bleeding disorders. Forty-seven of 53 boys (89%) receiving non-heat-treated factor VIII or prothrombin complex concentrates were anti-B19 IgG positive compared with 38% of their age-matched controls and 48% of children treated with cryoprecipitate. Acute B19 virus infection occurred in 2 boys 3-4 weeks after they had received the same batch of commercial factor VIII concentrate. Of 11 susceptible children who had only received heat-treated National Health Service factor VIII concentrate (8Y), 1 acquired anti-B19 IgG. This suggests that 8Y heat-treated concentrate has a much reduced risk of transmitting B19 virus and, by implication, other less heat-stable viruses such as human immunodeficiency virus.

摘要

对86名患有先天性出血性疾病的儿童进行了人细小病毒B19抗体患病率的测定。在接受非热处理的凝血因子VIII或凝血酶原复合物浓缩剂的53名男孩中，有47名（89%）抗B19 IgG呈阳性，相比之下，其年龄匹配的对照组中这一比例为38%，接受冷沉淀治疗的儿童中这一比例为48%。2名男孩在接受同一批次的商业凝血因子VIII浓缩剂3 - 4周后发生了急性B19病毒感染。在仅接受热处理的国民医疗服务体系（NHS）凝血因子VIII浓缩剂（8Y）的11名易感儿童中，有1名获得了抗B19 IgG。这表明8Y热处理浓缩剂传播B19病毒的风险大大降低，并且由此推断，传播其他热稳定性较差的病毒（如人类免疫缺陷病毒）的风险也大大降低。